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Abstract 
A number of human disorders are related to chronic iron overload, either of genetic or acquired origin. 
The multi-organ damage produced by iron excess leads, in adults and in children, to severe clinical 
consequences, affecting both quality of life and life expectancy. The diagnosis is increasingly based on a 
non-invasive strategy, resorting to clinical, biological and imaging data. The treatment rests on either 
venesection or chelation therapy, depending on the etiology. Major advances in the fields of molecular 
biology, pharmacology, and biotechnology pave the road for key improvements in the diagnostic and 
therapeutic management of the patients. 
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Iron overload diseases encompass a large spectrum of genetic and acquired disorders. The symptoms 
induced by chronic iron excess are close, whatever the etiology, and may cause significant morbidity 
and mortality representing a worldwide health problem. The diagnosis of iron overload is now based 
on a non invasive approach, resting on clinical, biological and imaging data. The treatment, which 
depends on the mechanisms underlying the development of iron overload, is mainly based on 
venesection or chelation therapy. However, in light of major advances in the pathophysiological 
understanding of these diseases(1), a number of promising innovative therapeutic approaches are 
emerging.    
1. SPECTRUM OF IRON OVERLOAD DISEASES (Fig.1) 
1.1. CAUSES 
1.1.1. GENETIC IRON OVERLOAD DISORDERS 
They correspond to various forms of hemochromatosis (HC)(2, 3). 
1.1.1.1.  HFE-related hemochromatosis. Also called Type 1-HC, it is by far the most 
frequent form of genetic iron overload disease. The usual underlying 
genotype is homozygosity for the C282Y mutation(4) (new HFE terminology 
p.Cys282Tyr). Type 1 HC is exclusively present in the caucasian (white) 
population, with  a prevalence of homozygosity close to 3 per thousand. 
C282Y homozygosity should be considered as a mere predisposition for the 
disease since phenotypic expression is quite variable (due to incomplete 
penetrance of the gene). It has thus been reported that approximately only 
1% of homozygote women and less than 30% of homozygote men may 
develop a fully expressed form of the disease(5), compromising both quality 
of life and life expectancy. Type 1 HC is an adult disease, most often 
expressed after 30 and 40 years old in men and women, respectively. It 
should also be noted that some data have pointed out the possible physical 
advantage provided by HFE mutations (6, 7). 
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1.1.1.2. Non HFE-related HC. They are rare diseases, but present in both caucasian 
and non-caucasian populations(8, 9). i) Type2 HC  corresponds to  a severe 
form of iron overload occurring in younger individuals (less than 30 years 
old), and therefore called juvenile HC. It is due to mutations of the 
hemojuvelin (HFE2 or HJV) gene or of the HAMP  (hepcidin) gene 
(corresponding to types 2A and 2B HC, respectively). ; ii) Type3 HC is due to 
mutations of the transferrin receptor 2 (TFR2) gene. Usually expressed in 
adults, it may also cause juvenile HC ; iii) Type4 HC. Due to mutations of the 
ferroportin (SLC40A1) gene, it is the only form of HC with a dominant mode 
of transmission. In its usual form (called type A), the mutations alter the 
export function of ferroportin. In the type B form, the mutations alter the 
hepcidin receptor function of ferroportin, leading to a refractoriness state 
toward hepcidin ; iv) Hereditary aceruloplasminemia (HA) (see below) may 
also be classified among  non-HFE related HC. 
1.1.1.3. Compared prevalences of HFE and non-HFE HC. Types 1, 2 and 3 HC are very 
rare as compared to HFE-HC. It has been reported that the predictive 
frequency of HFE pathogenic genotypes was approximately 1/1000, versus 
1/5000 000 for type 2A HC, 1/6000 000 for type 3 HC, and 1/180 000 000 for 
type 2B HC. Unexpectedly, the frequency for type 4 HC was close to that of 
type1 HC (1/1300), partly due to the dominant nature of the disease(9).   
   
1.1.2. ACQUIRED IRON OVERLOAD DISORDERS 
1.1.2.1. Iron supplementation. Chronic iron deficiency is a frequent worldwide 
condition(10). It may be due to iron dietary deficiency, especially in the 
frame of malnutrition, and requires usually oral iron supplementation. This 
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type of oral supplementation is not prone to induce iron overload, given the 
physiological limitations of duodenal iron absorption. In contrast, in 
parenteral iron administration, such as required in patients who undergo 
hemodialysis for chronic renal failure, iron excess can develop if iron therapy 
overcomes the needs(11). 
1.1.2.2. Transfusions. Repeated transfusions are a major cause of iron overload(12). 
Three main types of hematological diseases necessitate multiple 
transfusions : transfusion-dependent thalassemia, myelodysplastic 
syndromes, and aplastic anemia related to the therapeutic regimen applied 
in bone marrow stem cell transplantation. 
1.1.2.3.  Dyserythropoiesis. Whatever its hematological context, dyserythropoiesis 
can lead to potentially damaging body iron excess. This has been especially 
demonstrated in non-transfusion dependent thalassemia (thalassemia 
intermedia)(13). 
1.2. PATHO-PHYSIOLOGY 
1.2.1. IRON OVERLOAD MECHANISMS 
1.2.1.1. Increased cellular iron ingress :  
- Hepcidin deficiency is the prevailing mechanism in types 1, 2 and 3 HC as 
well as in dyserythropoiesis. The common mechanistic denominator is 
the decreased hepatic production of hepcidin which is the master 
regulator of systemic iron(14-16). This decrease is due, in HC, to the 
involved mutations and, in dyserythropoiesis, to the action of the bone 
marrow hormone erythroferrone (ERFE)(17, 18). The subsequent 
decreased plasma hepcidin concentration induces both an increased 
duodenal iron absorption, and an increased release by the spleen of the 
iron coming from the normal degradation of senescent erythrocytes 
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(erythrophagocytosis). The consequence is a chronic elevation of plasma 
iron concentration. Part of this iron is, as physiologically expected, taken 
up by its plasma carrier protein, transferrin, forming transferrin-iron. 
Transferrin-iron is essentially delivered to the bone marrow in order to 
contribute to the production of new red blood cells. But, due to the high 
levels of plasma iron, the quantity of circulating transferrin is insufficient 
to bind all of the metal, so that iron becomes partially present under 
another form, called non-transferrin bound iron (NTBI)(19, 20).  NTBI, 
which is likely bound to low molecular weight ligands such as citrate and 
acetate but also to albumin, has the very special kinetic property to be 
very avidly taken up, not by the bone marrow, but by various 
parenchymal cells, especially in the liver (hepatocytes), pancreas, and 
heart. Therefore, NTBI is considered as the main responsible for iron 
excess development in many organs.  
- Hepcidin refractoriness (type4B-HC). Although plasma hepcidin 
concentration is not decreased, the down-stream cellular consequences 
are similar to those occurring in quantitative hepcidin deficiency.  
- Iatrogenic excessive body iron intake : It corresponds to excessive 
parenteral administration of iron, either as iron per se (intravenous 
infusions) or through multiple transfusions, the erythrocytes being very 
iron rich (they represent half of the total body iron content).The fate of 
parenteral iron is to be stored within the reticuloendothelial system 
(macrophages), namely essentially in the spleen. This storage process is 
very fast for infused iron and postponed to the end of erythrocyte life for 
transfusional iron. Iron is subsequently released into the blood stream, 
leading to increased transferrin saturation and to NTBI production.  
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1.2.1.2. Decreased cellular iron egress : Type4A-HC (also called ferroportin disease) 
involves mutations which impair the iron export function of ferroportin. 
Ferroportin is the only known cellular iron exporter, and loss of this function 
leads to intracellular iron retention. In this situation, cellular iron overload 
affects mainly the spleen (due the high ferroportin activity at the 
macrophage level) and is accompanied by low plasma iron and transferrin 
saturation levels  (since cellular iron delivery into the plasma is impaired).  
Another genetic disease, in which iron overload results from an impairment 
in cellular iron egress, is HA(21). The underlying mechanism, although 
incompletely understood, involves the absence of ferroxidase activity which 
in turn may lead to ferroportin dysfunction(22).  
1.2.2. IRON OVERLOAD TOXICITY 
1.2.2.1. Role of reactive oxygen species (ROS) 
Iron is known for its involvement in the Fenton reaction leading to ROS 
production(23). The iron species involved in this toxic reaction is not 
transferrin-iron, but a special NTBI component, named labile plasma iron 
(LPI)(24-27). This iron species is able to target cellular membranes and nuclei, 
and is considered the main culprit for iron-related cellular and organ 
damage.   
1.2.2.2. Special considerations 
- Differential chronology of NTBI versus LPI involvement according to the 
mechanism of iron overload. In the setting of hepcidin deficiency (types 
1, 2, 3 and 4B-HC, as well as dyserythropoiesis) or of parenteral iron 
injection, the appearance of plasma NTBI  and LPI is an early process 
whereas, in transfusional iron overload, iron is first sequestered within 
the macrophages before being gradually released into the plasma, 
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generating NTBI and LPI. It means that, in transfusional iron overload,  
iron deposition concerns the spleen macrophages and other 
reticuloendothelial cells (Kupffer cells for the liver) first, parenchymal 
cells (especially hepatocytes) being subsequently involved. 
- Iron toxicity depends on the cellular type affected by iron deposition. 
Thus, iron is more damaging to parenchymal cells (typically the 
hepatocytes), than to reticuloendothelial cells (typically the 
macrophages).    
- The liver is a critical cross road in the process of body iron toxicity :i) as a 
major iron storage organ, it is capable, for a long period, to protect many 
other organs from becoming iron overloaded ; ii) however, when this 
role of reservoir is overwhelmed by the duration and intensity of iron 
overload, the liver may loose its « bulwark » property, opening the road 
for extra-hepatic iron toxicity ; iii) in chronic liver failure -whatever its 
etiology- the decreased production  by the hepatocytes of transferrin 
and hepcidin(28) may favor body iron overload and toxicity. Indeed, both 
mechanisms contribute to increase plasma transferrin saturation 
(through decreased plasma transferrin concentration and increased iron 
concentration, respectively), leading to the formation of plasma NTBI 
and LPI ; iv) the liver is a preferential target of iron toxicity. Being a 
storage organ is in fact a double-edged sword with the risk of progressive 
iron-related hepatocyte damage, leading to fibrosis, cirrhosis, and even 
hepatocellular carcinoma.    
- The role of cofactors acting as modulators of iron overload and toxicity is 
increasingly acknowledged. These factors can be environmental 
(acquired), such as menstruations or pregnancies which can contribute 
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to decrease iron overload, or chronic alcoholism which may aggravate 
hepatic iron toxicity(29). The cofactors can also be genetic. In HFE-HC, 
the presence of a mutation in the hepcidin promoter is associated with 
massive iron overload(30). Moreover, in this disease, GNAP(31), 
TMPRSS6(32), and PCSK7(33) polymorphisms have been reported to 
aggravate iron overload, to decrease iron overload, and to accentuate 
hepatic fibrosis , respectively. 
2. DIAGNOSTIC ASPECTS (Fig.2) 
2.1. GLOBAL DIAGNOSTIC STRATEGY 
It is a multi-step process. 
2.1.1. CLINICAL APPROACH 
It is the prerequisite of any diagnostic search, and should explore systematically  
general health and the various organs, since chronic iron overload corresponds 
to a systemic disease. Thus, the main syndromes, more ou less associated, are : 
chronic fatigue, joint pains, bone demineralization, melanodermia (increased 
skin pigmentation), liver signs (hepatomegaly, moderate transaminase increase), 
diabetes, or cardiac symptoms (rhythm disturbances, cardiac failure).   
2.1.2. BIOCHEMICAL APPROACH 
2.1.2.1. Plasma ferritin concentration. Usually defined by plasma ferritin values over 
300 µg/L in men and 200 µg/L in women, hyperferritinemia is the major first-
line biochemical parameter to explore total body iron stores. Whereas 
normal or low ferritinemia rules out iron overload, hyperferritinemia is highly 
suggestive of, but not necessarily synonymous with, iron overload. Indeed, it 
is essential to interpret rigorously hyperferritinemia since it can be related to 
a number of causes without significant body iron excess(34). Among those 
situations : i) inflammation since ferritin is an acute-phase reactant protein. 
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The macrophagic activation syndrome(35) is very close to this mechanism. 
Occurring in some infectious, hematological or auto-immune diseases it can 
be expressed by dramatic levels of hyperferritinemia ; ii) cytolysis, especially 
during acute or chronic hepatitis ; iii) alcoholism ; iv) metabolic 
hyperferritinemia which is likely to represent the most frequent cause of 
hyperferritinemia(36). Usually associated to plasma levels  below 1000 µg/L, 
metabolic hyperferritinemia is diagnosed on a number of convergent 
arguments : a) normal transferrin saturation (≤45%) ; b) diversely associated 
metabolic symptoms, such as overweight, increased arterial blood pressure, 
non-insulin dependent diabetes, hypercholesterolemia, hyperuricemia, and 
hepatic steatosis (as shown by ultrasound examination) ; c) absent or mild 
liver iron overload. V) The correlation of high plasma ferritin levels with 
organ iron burden depends on the cellular distribution of excessive iron 
deposits. Indeed, it has been reported, especially when comparing 
transfusion-dependent and non-transfusion dependent thalassemias, that  
similar levels of hyperferritinemia correspond to lower hepatic  iron 
concentrations  in transfusion-dependent thalassemia. (37) This may be due 
to the higher propensity of macrophages to produce ferritin.     
2.1.2.2. Plasma iron and transferrin saturation 
- Plasma iron. Its interpretation should consider some drawbacks, such as 
its nychtemeral cycle (with much lower values in the afternoon than in 
the morning), and numerous confounding factors which can either 
increase plasma iron(hemolysis, cytolysis), or decrease it (inflammation). 
- Plasma transferrin saturation (TS). It corresponds to the ratio of iron on 
transferrin, and is normally less than 45%. This parameter is still too 
often ignored, whereas its determination (which should, at best, be 
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based on two successive controls) provides, in iron overloaded 
situations, valuable diagnostic and prognostic indications. From the 
diagnostic viewpoint, iron overload with elevated TS orientates primarily 
towards hepcidin deficiency or iatrogenic excessive body iron intake. 
When TS is normal or low, the iron overload etiology may be type A 
ferroportin disease or hereditary aceruloplasminemia. From the 
prognostic viewpoint, TS levels ≥ 75%  are highly suggestive, in HC(25) as 
well as in thalassemia major(24), of plasma LPI which represents the 
potentially circulating toxic form of plasma iron.  
2.1.2.3. As to the novel biochemical plasma iron-related parameters, 
such as NTBI, LPI(38) or hepcidin(39), they presently remain mostly 
clinical research tools. 
2.1.3.  IMAGING APPROACH 
Magnetic resonance imaging (MRI) is the reference method for direct 
evaluation of body iron excess(40). Various techniques have been 
validated, consisting of relaxometry (T2* (41)/ R2 evaluation(42)) or 
signal-intensity ratio (SIR)(43) techniques. Although SIR cannot assess 
cardiac iron, it is particularly simple, quick, does not require special MRI 
equipment, and resorts to a software that is freely available on the web. 
Furthermore, SIR can, not only prove and quantify hepatic iron overload 
(the rate of hyposignal being positively correlated to the amount of iron 
excess), but also evaluate splenic iron, thus giving valuable 
pathophysiological informations. Indeed, the balance between liver and 
spleen iron overload provides a major diagnostic clue : schematically a 
« black » (i.e heavily iron overloaded) liver together with a « white » 
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spleen (no iron overload) is the typical profile observed in hepcidin 
cellular deprivation (related to hepcidin deficiency or refractoriness), 
whereas a black liver together with a black spleen is highly suggestive of 
transfusional iron overload. Moreover, a black spleen with a grey liver 
may suggest ferroportin disease.   
 
2.1.4.GENETIC APPROACH 
It should be guided by the first three, above mentioned, steps. Schematically, 
after having excluded acquired iron overload (no parenteral iron 
supplementation, transfusions, or dyserythropoiesis ), a careful interpretation of 
ferritin and transferrin saturation levels, together with the comparison of liver 
versus spleen MRI profiles, enables to engage relevant genetic studies(44). It 
must be mentioned that those specific genetic studies should be, at best, 
selected by clinical reference centers and require, for their determination, highly 
expert laboratories whose number remains very limited, stressing the 
importance of building appropriate international networks.  
2.1.4.1. Phenotype of hepcidin deprivation-related iron overload  
- In a given caucasian individual, searching for the C282Y mutation is to do 
first. Only C282Y homozygosity is diagnostically relevant. The frequent 
C282Y/H63D (p.His63Asp) compound heterozygosity cannot be  held 
responsible for clinically significant iron excess so that, in practice, there  
is no real indication for checking H63D. Exceptionally, other types of 
compound heterozygosities (involving C282Y as one of the two 
mutations), or type 4B ferroportin SLC40A1 mutations can be involved. 
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Looking for additional potential genetic risk factors (as mentioned above) 
could also be relevant. 
- In a non-caucasian individual, or in the absence of C282Y homozygosity 
in a caucasian person, specific genetic tests should be performed, at best 
in the frame of established reference centers.  In case of young patients 
(before the age of 30 yeass):  HJV (or HFE2), HAMP, and TFR2 mutations ; 
afer age 30: TFR2 mutations. 
2.1.4.2.Phenotype of ferroportin-related iron export deficiency  
It should lead to check the SLC40A1 mutations. 
2.1.4.3.Phenotype of HA 
Before performing the genetic test, a simple biochemical prerequisite is to 
ensure the absence of measurable  plasma ceruloplasmin(45). 
2.1.5.  HISTOLOGICAL APPROACH  
Classically(46), liver biopsy was performed for: i) proving iron overload (Perls staining) ; 
ii) quantifying iron overload (histological semi-quantification and/or biochemical 
determination fo liver iron concentration)  ; iii) orientating the etiology (hepatocyte 
versus macrophage iron deposition) ; iv) assessing liver fibrosis, and iv) searching for 
cofactors of hepatic toxicity, such as features of metabolic syndrome or alcoholism. 
2.2.OPTIMISING THE DIAGNOSTIC STRATEGY 
2.2.1. DIAGNOSING IRON OVERLOAD HAS BECOME A NON INVASIVE APPROACH 
Whereas, for a long time, performing a liver biopsy was an indispensable step, it is no 
more so for the following reasons : 
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- Proving, quantifying, and assessing indirectly cellular distribution (via the 
balance between liver and spleen iron deposition) can be accurately 
achieved by MRI. 
- Transient elastography is increasingly performed, as a non invasive 
surrogate for liver biopsy, to assess liver fibrosis(47).   
2.2.2. NEW PROMISING BIOLOGICAL TOOLS ARE EMERGING 
  -  A number of recent biochemical parameters should, in the near future, be 
more and more applied to investigate disorders of iron metabolism. Among them, the 
measurements of plasma NTBI, LPI, and possibly hepcidin concentrations. 
  - The recent advances in molecular biology, especially through next 
generation sequencing (NGS), are already transforming the genetic diagnosis for iron- 
related disorders(48). This high throughput approach is a powerful way to identify 
mutations. However, it raises interpretation issues since it is able to identify a number of 
new variants of which it is difficult to know whether or not they are harmful.    
2.2.3. CLINICAL UTILITY TO PROPOSE THE CONCEPT OF HEPCIDIN-DEPRIVATION 
SYNDROME (HDS) 
The HDS syndrome, observed in all cases of HC (but type A ferroportin disease) and in 
dyserythropoiesis, can be characterized by the association of increased plasma 
transferrin saturation, parenchymal (hepatocyte) iron deposition, and absence of splenic 
iron overload. It exposes to severe complications of iron overload, due to the 
parenchymal LPI impact.    
2.2.4  SETTING UP NATIONAL AND INTERNATIONAL REFERENCE CENTERS AND 
NETWORKS, for improving the diagnosis of iron overload disorders related to rare HFE or 
non-HFE mutations, should be part of the health decision-maker policies.  
3.THERAPEUTIC ASPECTS (Fig.3) 
3.1.CURRENTLY AVAILABLE THERAPEUTIC TOOLS AND STRATEGIES 
 14 
 
3.1.1. VENESECTION THERAPY 
3.1.1.1. Rationale. To eliminate excessive stored iron by inducing its release into the 
blood stream through the recycling effect of repeated erythrocyte withdrawal.  
3.1.1.2. Indications : Mainly the  hepcidin deprivation syndrome,  as present in types1, 2, 
3, and 4B-HC. Residual iron overload after blood stem cell transplantation can also be 
successfully eliminated by bloodletting(49). 
3.1.1.3. Method. The initial phase (called induction phase) consists of iron overload 
elimination. Venesections, of approximately 7ml/kg body weight (without exceeding 
550mL)(50), should be done on a regular weekly basis.  
3.1.1.4. Tolerance monitoring. It is evaluated both on clinical data (general tolerance ; 
blood pressure) and on hemoglobin (Hb) levels which should not decrease below 11g/dL 
or by more than 2g compare to baseline levels. 
3.1.1.5. Efficacy follow-up. It  is based on plasma ferritin levels, checked every month 
until the values reach the upper normal limits, and every two weeks thereafter, until the 
final goal of ferritinemia levels close to 50 µg/L is reached. It should be  kept in mind that 
transferrin saturation levels remain high until the very end of the induction phase, so that 
this parameter is not appropriate for evaluating the gradual decrease of iron excess due 
to the venesections. After iron depletion has been achieved,  the maintenance phase 
starts, lasting, theoretically, for the whole life, and aiming to maintain ferritin levels close 
to 50 µg/L. It usually consists of one venesection every 2 to 4 months. 
3.1.1.6. Results. In HC due to hepcidin deficiency, venesection therapy is globally well 
tolerated although, in a recent international survey on 210 type HC patients(51), 52% of 
induction patients and 37% of maintenance patients experienced side effects “always” 
or “most of the time” after phlebotomy. The overall efficacy to remove iron overload is 
excellent and many symptoms improve ; however, the joint symptoms may not been 
improved and even deteriorate or appear under depleting treatment(52, 53).  
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3.1.2. CHELATION 
3.1.2.1. Rationale. To use a compound which, after having bound iron at the cellular 
and/or plasma compartment levels,  eliminates the captured iron through the urinary 
and/or intestinal routes.  
3.1.2.2. Indications. Chelation is indicated whenever significant iron overload occurs in 
the context of chronic anemia, encompassing hemoglobinopathies (mostly major and 
intermedia thalassemias) and selected cases of myelodysplasia.    
3.1.2.3. Methods. Three main compounds are available(54). The oldest one is 
desferrioxamine or deferoxamine (DFO) (Desferal©). As an hexadentate (one chelator 
molecule binds one iron atom) it is a powerful and very steady chelator. It is eliminated 
via the urinary and fecal route.  It needs to be administered parenterally and has a very 
short half-life (20-30 min). Deferiprone (DFP) (Ferriprox©) has been the first oral 
chelator. It is a bidentate compound (three molecules are needed to bind one iron atom) 
with a relatively short half-life (1.5-2.5h). Its elimination is essentially through the urinary 
route. Deferasirox (DFX) (Exjade©) is the most recent oral chelator. It is a tridentate 
compound (two molecules for binding one iron atom) with a long half-life (10-16h). It is 
essentially eliminated through the biliary and then fecal route. 
3.1.2.4. Tolerance.  The major DFO drawback is it way of administration. The chelator is 
usually administered as a prolonged subcutaneous infusion, using a portable pump, 12 
hours a day,  at least five days a week, therefore raising important compliance issues, 
especially in children. DFP requires  a three daily dose administration (a liquid 
formulation has been designed to avoid taking too many tablets) and may induce, 
exceptionally but unpredictably, agranulocytosis, therefore leading to a systematic 
monitoring, on a weekly basis, of the blood cell count. DFX presents the advantage of 
being taken only once a day. It can result in, usually transient, renal failure (creatinine 
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increase), gastrointestinal symptoms (expected to be lessened by a new formulation), 
skin rashes, or transaminase increase.  
3.1.2.5. Efficacy.  All three compounds are efficient. DFP has an interesting efficacy on    
cardiac iron overload(55). DFX is able to negativate iron balance and to exert beneficial 
hepatic effects  on iron-related hepatic inflammation and fibrosis(56). 
 
3.1.3 FAMILY SCREENING (GENETIC DISEASES) 
3.1.3.1. General strategy. Family screening is based on the following three main data : 
i) the genetic profile that has been identified in the proband and serves as a marker to evaluate 
genetic predisposition among the relatives, ii) the phenotypic markers, combining plasma 
transferrin saturation and ferritin levels, and iii) the recessive or dominant mode of 
transmission of the disease. 
3.1.3.2. Differential strategies :  
- Quantitative hepcidin deficiency-related HC (types1, 2, or 3 HC).  i) Type1 
(C282Y/C282Y)-HC(44). Only C282Y homozygosity exposes to the disease risk, keeping however 
in mind that homozygosity does not mean « disease » (due the partial penetrance of the gene). 
Siblings (genetically explored only after the age of 18) are the primary at risk relatives. 
However, given the high HFE mutation prevalence, it is recommended to screen genetically 
also the offspring (after age 18). For the parents, it is usually sufficient to check the phenotypic 
markers, limiting the genetic study to the cases with phenotypic suggestion of established iron 
excess. ii) Type2 –HC. Being exceptional, recessive, and juvenile diseases, screening should 
focus on the siblings (whatever their age). iii) Type3-HC. The screening strategy is close to that 
of Type1-HC with the differences that, being a rare disease, the offspring are not at risk, and 
that, since young individuals may be affected, siblings should be explored whatever their age. 
 17 
 
- Types4 A and B – HC.  The screening procedure should consider both the identical 
dominant mode of transmission, and the distinct phenotypic expression of these two types of 
ferroportin diseases.  
3.2. OPTIMISING THE THERAPEUTIC STRATEGY 
3.2.1. CURATIVE ASPECTS : WAYS TO IMPROVE IRON OVERLOAD REMOVAL 
3.2.1.1.  Hepcidin-deprivation HC (types 1, 2, 3, 4B-HC) :  In the most severe forms of adult or 
juvenile HC(57), combining venesections and chelation may be an option.The interest of 
adjoining new forms of therapies, such as hepcidin induction(58) (excluding of course type4B-
HC which involves hepcidin refractoriness) through exogenous administration(59) or 
endogenous stimulation of hepcidin (via, for instance, stimulation of the BMP-SMAD signalling 
pathway), needs further investigation.  
3.2.1.2. Ferroportin iron export deficiency-HC (type4A-HC) : How to stimulate this ferroportin 
property remains a research objective. 
3.2.1.3. Transfusional and dyserythropoietic iron overload : With the available chelators, there 
are two major trends for ameliorating chelation efficacy. One is to increase the doses with the 
risk of increasing side effects. The other option is to combine chelators either by simultaneous 
or sequential administration, and promising results have already been obtained(60, 61).  A 
further strategy is to find new chelators, closer to an ideal profile in terms of efficacy, tolerance 
and cost. Innovative therapies could resort to apotransferrin supplementation(62) or TMPRSS6 
inhibition(63). 
3.2.1.4. Whether antioxidant therapy could be a significant favorable adjunct remains to be 
clinically fully demonstrated(64-66).   
3.2.2 PREVENTIVE ASPECTS 
3.2.2.1 GENETIC DISEASES (Type1-HC) 
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- Practical measures should be reinforced to diagnose and treat the disease as early as 
possible. They include : i) Increased awareness of the disease among the medical community, 
general population and health authorities, with the critical help of patient associations ; ii) 
Developing family screening centers which are necessary when considering the frequent 
geographical scatttering of the relatives ; iii) Setting up national and international reference 
centers in the field of genetic iron overload disorders ; iv)  As to the  mass screening of 
caucasian populations, it remains debated but seems a reasonable preventive goal in view of 
the following data : HFE-HC is a frequent disease, with a long clinically asymptomatic phase, an 
easy and non invasive diagnosis, and furthermore an effective treatment. 
- From the medical and scientific viewpoint, preventive improvements should come 
from two main directions : one is to identify predictive markers of phenotypic expression, 
another one is to investigate the interest of hepcidin supplementation, especially for 
preventing iron overload development in early diagnosed (and potentially expressing) 
homozygotes, and to avoid iron overload reconstitution after the end of the induction phase. 
3.2.2.2. ACQUIRED DISEASES (TRANSFUSIONAL IRON OVERLOAD) 
Associating plasma iron, transferrin saturation and ferritin determination together with 
MRI assessment of iron overload, should permit to start the chelation therapy as early as 
possible. 
 
In conclusion, the iron overload field concerns a wide variety of potentially severe 
diseases of genetic or acquired origin. Key advances in the knowledge of iron metabolism 
joined to major biological, pharmacological and technological improvements have considerably 
improved the diagnostic and therapeutic approaches of these diseases. The active ongoing 
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research in these domains is opening highly promising roads for continuous amelioration of 
patient care.   
EXPERT COMMENTARY 
In contrast to iron deficiency which is widely recognized as a major health problem, iron 
overload disorders remain poorly known to the general population and even to the medical 
community, probably largely due to the fact that iron remains, in our collective unconscious, 
synonymous with strentgh and good health. It is therefore important to disseminate 
informations concerning the major recent advances in the diagnostic and therapeutic 
management of these iron overload disorders which, whatever their genetic or acquired origin, 
may severely impact the quality of life and life expectancy of the affected adults or children. 
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FIVE-YEAR VIEW 
 
- For genetic iron overload, especially related to hepcidin deficiency, many 
new variants will be discovered and it is hoped that some of them will 
permit to predict the phenotypic expression of the genetic 
predisposition. This prediction should ideally concern not only the 
amount of iron overload expected in the absence of treatment but the 
target organs likely to be affected in case of iron excess. An earlier 
diagnosis, thanks to increase awareness of the diseases and to extended 
phenotypic screening (based on plasma iron and/or transferrin 
saturation and/or ferritin levels), should, together with novel predictive 
markers of phenotypic expression, permit to initiate preventive therapy, 
ideally consisting of hepcidin supplementation. 
- For transfusional iron overload, the diagnosis should benefit from 
greater accessibility to MRI permitting to start the treatment as soon as 
possible. One cannot exclude that novel oral  iron chelators will be 
developed during this period but defining the best combined strategies 
with the existing chelators appear the most promising orientation. 
Whether hepcidin supplementation will have a significant role in the 
therapeutic approach of this type of iron overload is a very stimulating 
perspective.  
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KEY ISSUES 
 
• Iron is crucial for life but iron overload, like iron deficiency, can be severely 
deleterious for the human body. 
• Iron overload can be of genetic or acquired origin. Hemochromatosis and 
transfusional iron overload are the respective archetypes of the corresponding 
diseases. 
• Hemochromatosis is due to either increased iron entry in the cells or decreased 
cellular iron egress. Hepcidin and (usual) ferroportin deficiencies are the respective 
mechanisms underlying these two types of hemochromatosis. 
• Iron overload due to hepcidin deficiency is characterized by high plasma iron and 
transferrin saturation together with parenchymal (essentially hepatocyte) iron 
deposition. 
• Plasma NTBI (non-transferrin bound iron) and its LPI (labile plasma iron) component 
are new iron species, responsible for iron overload and iron toxicity, respectively. 
• MRI (magnetic resonance imaging) has become the non-invasive technique of 
reference for assessing hepatic (and splenic) iron load. 
• Next generation sequencing is transforming the genetic diagnostic strategy and 
should be handled by expert centers.  
•  Venesection therapy remains the basis for removing iron excess in diseases related 
to hepcidin deficiency and could be, in the future, associated with (or replaced by) 
hepcidin supplementation. 
• Chelation therapy has greatly benefited from the introduction of oral chelators. 
Combining different chelators represents a promising therapeutic perspective. 
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FIGURE 1. Iron overload disease spectrum. BMSCT : bone marrow stem cell transplantation. 
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FIGURE 2. Schematic strategy for the diagnostis of iron overload diseases. M: men ; W: women. Black 
liver or spleen : heavy iron overload  (appearing black due to very low MRI signal) ; Grey liver: 
moderate iron overload ; White liver or spleen: no iron overload (normal MRI signal).* 
Clinical symptoms mean: chronic fatigue, joint and bone symptoms, hepatic, pancreatic or 
cardiac symptoms. ** after having ruled out common causes of hyperferritinemia (metabolic 
syndrome, inflammation, cytolysis, alcoholism). 
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FIGURE 3. Schematic strategy for the treatment of iron overload diseases. 
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